AI isn’t close to curing cancer. This startup says it knows what it will take.
It’s the data, stupid.
Biotech & Health
Daniel Ek’s body-scanning startup Neko Health opens first US office, in New York
The scanning and bloodwork health startup founded by Spotify’s founder will officially launch in New York in about a month.
CareCloud begins to notify hundreds of thousands after hackers stole medical records
The health tech data giant, which handles vast amounts of patients’ medical data, said hackers struck one of its protected health data stores.
Science Corporation’s vision-restoring chip wins EU approval
“The thing that the space needs is a company making $100 million a year of revenue,” Science Corp. CEO Max Hodak said.
Dimension Capital’s $800M third fund shows the intersection of science and compute is booming
The four-year-old firm’s latest fund is 60% larger than its second vehicle announced 18 months ago.
Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation
The de-extinction startup is looking to double or triple its previous valuation, according to the report.
Period tracker Stardust shares users’ health data with analytics firm, says Mozilla research
One period tracker app tested by Mozilla was ‘squeaky clean,’ while another app was seen sharing users’ health data with an analytics company, underscoring vast differences in user privacy among these apps.
Daniel Ek’s body-scanning startup Neko Health raises another $700M
Neko Health has developed proprietary body-scanning technology, which it couples with bloodwork, to assess a person’s health.
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences.
Reed Jobs would rather talk about curing cancer than his last name
When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in roughly the same window, creating all kinds of new opportunities; and AI has gone from a curiosity to, in Jobs’s words, a huge part of what Yosemite does. “I didn’t expect Yosemite to be moving this fast,” he said.